Patient
SITE004-0031
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE004 (DEU) (Dr. Tanaka)
consented 2025-10-01
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-08-13 (study day 129); relationship: RELATED
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-06-09 (study day 64); relationship: NOT RELATED
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 42); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: UNKNOWN; onset 2022-05-09 (study day 33); relationship: NOT RELATED
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 24); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 24); relationship: NOT RELATED; serious criteria: life-threatening
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-12 (study day 6); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-04-09 (study day 3); relationship: NOT RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.